Ronald D Perrone

List of Publications by Year
in descending order

88 papers	7,004 citations	87888 38 h-index	60623 81 g-index
90 all docs	90 docs citations	90 times ranked	5053 citing authors

#	Article	IF	Citations
1	Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2012, 367, 2407-2418.	27.0	1,267
2	Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2017, 377, 1930-1942.	27.0	420
3	Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2014, 371, 2255-2266.	27.0	392
4	Autosomal dominant polycystic kidney disease. Lancet, The, 2019, 393, 919-935.	13.7	337
5	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 128-139.	11.4	223
6	Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2014, 371, 2267-2276.	27.0	221
7	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes and Endocrinology,the, 2019, 7, 115-127.	11.4	199
8	Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: Contribution of extrarenal complications to mortality. American Journal of Kidney Diseases, 2001, 38, 777-784.	1.9	171
9	A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. Journal of the American Society of Nephrology: JASN, 2018, 29, 2458-2470.	6.1	163
10	Consensus Expert Recommendations for the Diagnosis and Management of Autosomal Recessive Polycystic Kidney Disease: Report of an International Conference. Journal of Pediatrics, 2014, 165, 611-617.	1.8	138
11	Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 2872-2884.	6.1	136
12	The HALT Polycystic Kidney Disease Trials. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 102-109.	4.5	125
13	Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrology Dialysis Transplantation, 2018, 33, 477-489.	0.7	119
14	Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 803-811.	4.5	118
15	Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal) Tj ETQq1 1 0.784314 rgBT /Overloc 2011, 57, 692-699.	1.9	115
16	Vascular complications in autosomal dominant polycystic kidney disease. Nature Reviews Nephrology, 2015, 11, 589-598.	9.6	110
17	Performance of Creatinine-Based GFR Estimating Equations inÂSolid-Organ Transplant Recipients. American Journal of Kidney Diseases, 2014, 63, 1007-1018.	1.9	103
18	Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2018, 29, 571-578.	6.1	101

#	Article	IF	Citations
19	Health-Related Quality of Life in Patients With Autosomal DominantÂPolycystic Kidney Disease and CKD Stages 1-4: AÂCross-sectional Study. American Journal of Kidney Diseases, 2014, 63, 214-226.	1.9	93
20	Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease inÂPatients With Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2017, 2, 442-450.	0.8	92
21	Liver Involvement in Early Autosomal-Dominant Polycystic Kidney Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 155-164.e6.	4.4	90
22	Discussing Conservative Management With Older Patients With CKD: An Interview Study of Nephrologists. American Journal of Kidney Diseases, 2018, 71, 627-635.	1.9	87
23	International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. Nature Reviews Nephrology, 2019, 15, 713-726.	9.6	86
24	Dietary salt restriction is beneficial to the management of autosomal dominant polycysticÂkidney disease. Kidney International, 2017, 91, 493-500.	5.2	80
25	Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. Journal of the American Society of Nephrology: JASN, 2017, 28, 1592-1602.	6.1	78
26	Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney International, 2012, 81, 577-585.	5.2	74
27	Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. Journal of the American Society of Nephrology: JASN, 2019, 30, 1756-1769.	6.1	71
28	Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. American Journal of Human Genetics, 2022, 109, 136-156.	6.2	62
29	Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: AÂPilot Randomized Controlled Trial. American Journal of Kidney Diseases, 2016, 68, 882-891.	1.9	54
30	Metabolomic Alterations Associated with Cause of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1787-1794.	4.5	54
31	Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney International, 2019, 96, 159-169.	5.2	51
32	Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). Kidney International, 2021, 100, 684-696.	5.2	48
33	Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrology Dialysis Transplantation, 2017, 32, 1262-1262.	0.7	47
34	A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology, 2018, 47, 352-360.	3.1	47
35	Characterizing Approaches to Dialysis Decision Making with Older Adults. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1188-1196.	4.5	47
36	Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrology Dialysis Transplantation, 2016, 31, 1887-1894.	0.7	46

#	Article	IF	Citations
37	Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769335.	1.1	45
38	Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney International, 2020, 97, 370-382.	5.2	44
39	Cardiac Magnetic Resonance Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2508-2515.	4.5	43
40	Management of ESRD in Patients With Autosomal Dominant Polycystic Kidney Disease. Advances in Chronic Kidney Disease, 2010, 17, 164-172.	1.4	41
41	The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight, 2020, 5, .	5.0	41
42	Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2017, 92, 796-808.	5.2	40
43	Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial. Kidney International Reports, 2016, 1, 213-220.	0.8	37
44	Tolvaptan and Kidney Pain in Patients With Autosomal DominantÂPolycystic Kidney Disease: Secondary Analysis FromÂa Randomized Controlled Trial. American Journal of Kidney Diseases, 2017, 69, 210-219.	1.9	37
45	Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrology Dialysis Transplantation, 2017, 32, gfw294.	0.7	36
46	Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument. American Journal of Kidney Diseases, 2018, 71, 225-235.	1.9	36
47	The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations. American Journal of Kidney Diseases, 2018, 72, 302-308.	1.9	29
48	Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Current Hypertension Reviews, 2018, 13, 109-120.	0.9	27
49	Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 48-58.	4.5	26
50	Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1267-1278.	4.5	24
51	Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. American Journal of Kidney Diseases, 2020, 76, 361-373.	1.9	23
52	Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2020, 31, 1640-1651.	6.1	22
53	Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data. ClinicoEconomics and Outcomes Research, 2015, 7, 123.	1.9	21
54	Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). American Journal of Kidney Diseases, 2015, 66, 583-590.	1.9	21

#	Article	IF	Citations
55	Standardised Outcomes in Nephrologyâ€"Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials, 2017, 18, 560.	1.6	20
56	Identifying patientâ€important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology, 2019, 24, 1214-1224.	1.6	20
57	A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2017, 2, 451-460.	0.8	19
58	Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2017, 32, gfw060.	0.7	17
59	Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). American Journal of Kidney Diseases, 2019, 73, 533-541.	1.9	16
60	Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. American Journal of Kidney Diseases, 2020, 76, 213-223.	1.9	16
61	The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations. Kidney International Reports, 2020, 5, 801-812.	0.8	16
62	Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology, 2017, 45, 257-266.	3.1	15
63	The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression. BMC Nephrology, 2017, 18, 169.	1.8	15
64	Tolvaptan in ADPKD Patients With Very Low Kidney Function. Kidney International Reports, 2021, 6, 2171-2178.	0.8	15
65	Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone- System Blockade?. Current Hypertension Reviews, 2018, 14, 39-47.	0.9	13
66	Secondary hyperaldosteronism stimulates acidification in rat distal colon. Pflugers Archiv European Journal of Physiology, 1990, 416, 639-645.	2.8	11
67	Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies. Kidney Medicine, 2021, 3, 536-545.e1.	2.0	11
68	Association of Baseline Urinary Metabolic Biomarkers with ADPKD Severity in TAME-PKD Clinical Trial Participants. Kidney360, 2021, 2, 795-808.	2.1	10
69	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 291-303.	6.1	10
70	Toward Patient-Centered Innovation. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1522-1530.	4.5	8
71	Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2018, 3, 619-624.	0.8	7
72	Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial. Kidney360, 2020, 1, 1363-1372.	2.1	7

#	Article	IF	Citations
73	A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD. Kidney International Reports, 2020, 5, 790-800.	0.8	6
74	Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 374-384.	4.5	6
75	ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing. American Journal of Kidney Diseases, 2018, 71, 294-296.	1.9	5
76	â€˜A sword of Damoclesâ€™: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. BMJ Open, 2020, 10, e038005.	1.9	5
77	Aldosterone and PCO2 enhance K-dependent chloride absorption in rat distal colon. Pflugers Archiv European Journal of Physiology, 1990, 416, 632-638.	2.8	4
78	A Systematic Review of Reported Outcomes in ADPKD Studies. Kidney International Reports, 2022, 7, 1964-1979.	0.8	4
79	Tolvaptan or transplant: why wait?. Kidney International, 2020, 98, 286-289.	5.2	3
80	The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 1801-1812.	6.1	3
81	Assessing Risk of Progression in ADPKD. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 134-136.	4.5	3
82	How Does a Patient's Primary Renal Disease Impact Chronic Dialysis Management?. Seminars in Dialysis, 2015, 28, 470-473.	1.3	1
83	Closeout of the HALT-PKD trials. Contemporary Clinical Trials, 2015, 44, 48-55.	1.8	1
84	PKD1 Compared With PKD2 Genotype and Cardiac Hospitalizations in the Halt Progression of Polycystic Kidney Disease Studies. Kidney International Reports, 2022, 7, 117-120.	0.8	1
85	Autosomal Dominant PKD in Patients With PKD2 Mutationsâ€“AÂBenign Disorder?. American Journal of Kidney Diseases, 2017, 70, 456-457.	1.9	0
86	Management of ADPKD Today. , 2018, , 243-262.		0
87	A 51-Year-Old Renal Transplant Recipient With Abdominal Pain. Clinical Infectious Diseases, 2020, 71, 453-454.	5.8	0
88	Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD. Kidney International Reports, 2021, 6, 1032-1040.	0.8	0